コンテンツへスキップ
Merck

Anti-tumor activity of a new series of benzoxazepine derivatives in breast cancer.

Bioorganic & medicinal chemistry letters (2009-11-26)
Krishnananda Samanta, Bandana Chakravarti, Jitendra Kumar Mishra, Shailendra Kumar Dhar Dwivedi, Lakshma Vadithe Nayak, Preeti Choudhry, Hemant Kumar Bid, Rituraj Konwar, Naibedya Chattopadhyay, Gautam Panda
要旨

A series of new benzoxazepine derivatives substituted with different alkoxy and aryloxy group were synthesized comprising synthetic steps of Mitsunobu reaction, lithium aluminum hydride (LAH) reduction, followed by debenzylation and finally intramolecular Mitsunobu cyclization. The new benzoxazepines specifically inhibited growth of breast cancer cell lines, MCF-7 and MDA-MB-231, but lack cytotoxicity to normal HEK-293 cells. The cell growth inhibition induced by the active compounds was due to cell cycle arrest at G(0)/G(1) phase. The active compound could cause significant reduction in tumor volume of MCF-7 xenograft tumor in nude mice model and their activity was comparable to that of tamoxifen citrate at 16mgkg(-1) dose at 30days of treatment. The identified most active compounds of the series have specific advantages as anti-cancer agent in breast cancer than tamoxifen.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
水素化アルミニウムリチウム, powder, reagent grade, 95%
Sigma-Aldrich
水素化リチウムアルミニウム 溶液, 1.0 M in THF
Sigma-Aldrich
水素化リチウムアルミニウム 溶液, 2.0 M in THF
Sigma-Aldrich
水素化アルミニウムリチウム, pellets, reagent grade, 95%
Sigma-Aldrich
水素化リチウムアルミニウム 溶液, 1.0 M in diethyl ether
Sigma-Aldrich
水素化アルミニウムリチウム, hydrogen-storage grade
Sigma-Aldrich
水素化リチウムアルミニウム 溶液, 2.3 M in 2-methyltetrahydrofuran
Sigma-Aldrich
水素化アルミニウムリチウム, ≥97.0% (gas-volumetric)
Sigma-Aldrich
水素化リチウムアルミニウム 溶液, 0.5 M in 2-methoxyethyl ether
Sigma-Aldrich
水素化アルミニウムリチウム, ≥97.0% (gas-volumetric), tablet (5 g each)